CS
UTMD icon

Credit Suisse’s Utah Medical Products UTMD Stock Holding History

Credit Suisse’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17
Closed -$1K – 4142
2022
Q3 		$1K Buy
17
+9
+113% +$794 ﹤0.01% 3943
2022
Q2 		$0 Buy
+8
New +$682 ﹤0.01% 4337
2014
Q2 		– Sell
-3,661
Closed -$211K – 4811
2014
Q1 		$211K Sell
3,661
-1,108
-23% -$60.5K ﹤0.01% 4321
2013
Q4 		$273K Buy
+4,769
New +$262K ﹤0.01% 4139

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's UTMD Position: Q4 2022 in Review

Credit Suisse sold out of Utah Medical Products (UTMD) in Q4 2022, closing a stake of 17 shares — an estimated $1K sold.

Credit Suisse first reported a position in UTMD in Q4 2013 and held it in 4 quarters. The position peaked at $273K in Q4 2013. 82 funds tracked by Wall St. Rank hold UTMD as of Q4 2022.

  • Credit Suisse reported no remaining Utah Medical Products position as of Q4 2022 after selling out during the quarter.
  • Credit Suisse sold 17 Utah Medical Products shares in Q4 2022, an estimated $1K.
  • Credit Suisse first reported a position in Utah Medical Products in Q4 2013 and held it in 4 quarters.
  • Credit Suisse's Utah Medical Products position peaked at $273K in Q4 2013.
  • 82 funds tracked by Wall St. Rank held Utah Medical Products as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.